Posted by Questionmark on November 3, 2008, at 1:03:32
In reply to Re: Tyrima study, posted by Medline on November 1, 2008, at 14:12:22
> I don't quite get it: Is Tyrima a simple reversible MAO-A inhibitor? Then how is it superior to Moclobemide? A brain selective MAO-A+MAO-B inhibitor would be a novel agent.
See, that's exactly what I was thinking Medline. I couldn't really find much info on it, but based on the little I could it doesn't seem to have any qualities beyond half-life that would seem to make it superior to moclobemide at all.
But, that said, bleauberry brings up a very good point in that just because two drugs are in the same specific class doesn't mean they are going to be exactly the same. The irreversible MAOIs are a great example of this. But, with Parnate and Nardil we are aware of some of their different pharmacological properties-- as is even the case with some of the SSRIs-- but with moclobemide and Tyrima i am not yet aware of any differences. So, i dunno.
poster:Questionmark
thread:860116
URL: http://www.dr-bob.org/babble/20081027/msgs/860498.html